ArticleBMC complementary medicine and therapies2025
Combining network pharmacology and molecular docking to explore the pharmacological mechanism of Codonopsis Radix.-Hedysarum Multijugum Maxim.-Atractylodes Macrocephala Koidz. in treating lung cancer.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Zhuangdu Quhan Mixture Alleviates Ankylosing Spondylitis in Mice by Inhibiting the Interleukin-17 Signaling.Biomedical chromatography : BMC · 2026Article
- Postoperative rupture of bronchial stump inducing severe hemorrhage from pulmonary artery trunk: a case report.Journal of cardiothoracic surgery · 2026Article
- AC decoction augments chemotherapy in NSCLC by reshaping the tumor immune microenvironment: attenuating Tregs and enhancing CD8Scientific reports · 2026Article
- Dysosma versipellis is associated with cholestatic hepatotoxicity potentially involving FXR-SHP-CYP7A1/BSEP-MRP2 axis disruption: A multi-omics-driven mechanistic investigation based on the toxicological evidence chain (TEC) concept.Journal of molecular histology · 2026Article
- Therapeutic association and mechanistic exploration of modified Sijunzi Decoction in radiation-induced sinusitis: an integrated retrospective analysis and network pharmacology study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo explore the potential mechanism of the treatment of lung cancer (LC) with Codonopsis Radix.-Hedysarum Multijugum Maxim.-Atractylodes Macrocephala Koidz. (CHA).
methodsThe active ingredients and targets of CHA were obtained from TCMSP and SwissTargetPrediction databases. LC-related genes were obtained from MalaCards, GeneCards and DisGenNET databases. A protein-protein interaction network was constructed using STRING database, and analyzed with Cystoscape software. The core targets of CHA in LC treatment were determined by topological analysis, and functional annotation of these targets was performed via Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. The binding ability of the target to the active ingredient was evaluated by molecular docking. CCK-8 assay, Transwell assay, qRT-PCR, Western blot and lung metastasis model in nude mice were used to evaluate the effects of CHA on the viability, migration and invasion of LC cells.
results27 active components and 411 common targets of CHA in lung cancer treatment were obtained. The common targets were associated multiple biological processes and pathways including PI3K-AKT pathway. 12-senecioyl-2E,8E,10E-atractylentriol, 14-acetyl-12-senecioyl-2E,8Z,10E-atractylentriol, astrapterocarpan, isoflavanone, (R)-Isomucronulatol were identified as the main bioactive components of CHA, and SRC, HSP90AA1, AKT1, EGFR, ESR1 were identified as core targets of CHA in LC treatment. The bioactive ingredients had good binding ability with the core targets. CHA significantly inhibited the viability, migration and invasion of LC cells, and also suppressed the transcription of core genes, and repressed the activation of PI3K/AKT pathway.
conclusionFor LC, CHA exerts tumor-suppressive effects through various bioactive components, acting on multiple targets and signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.